GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $226,837.74 in Stock

Key Points

• Katherine Stueland, the CEO of GeneDx Holdings Corp., sold 2,154 shares of the company's stock for $226,837.74, resulting in a 38.51% reduction in her ownership.
• GeneDx reported a significant earnings beat with $0.50 earnings per share for the quarter, exceeding analysts' expectations of $0.10 and generating revenue of $102.69 million.
• The stock has experienced fluctuations, hitting a recent low of $25.32 and a high of $117.75 over the past year, with analysts giving it a consensus rating of "Moderate Buy."

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 2,154 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total transaction of $226,837.74. Following the completion of the transaction, the chief executive officer directly owned 3,440 shares in the company, valued at $362,266.40. The trade was a 38.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, July 9th, Katherine Stueland sold 3,220 shares of GeneDx stock. The shares were sold at an average price of $93.00, for a total value of $299,460.00.
• On Tuesday, July 1st, Katherine Stueland sold 9,657 shares of GeneDx stock. The shares were sold at an average price of $90.94, for a total value of $878,207.58.

GeneDx Trading Up 2.7%

Shares of WGS stock traded up $2.79 on Monday, hitting $104.39. 214,995 shares of the stock traded hands, compared to its average volume of 1,087,363. The firm's 50-day moving average price is $80.02 and its two-hundred day moving average price is $83.14. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The stock has a market capitalization of $2.98 billion, a PE ratio of 2,087.90 and a beta of 2.02. GeneDx Holdings Corp. has a twelve month low of $25.32 and a twelve month high of $117.75.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Hedge Funds Weigh In On GeneDx

Several hedge funds have recently bought and sold shares of the company. Chung Wu Investment Group LLC grew its stake in GeneDx by 8.2% during the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company's stock worth $305,000 after purchasing an additional 250 shares in the last quarter. GAMMA Investing LLC raised its stake in GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after buying an additional 264 shares in the last quarter. Palisades Investment Partners LLC boosted its stake in GeneDx by 0.4% in the first quarter. Palisades Investment Partners LLC now owns 83,913 shares of the company's stock valued at $7,432,000 after acquiring an additional 309 shares in the last quarter. Sterling Capital Management LLC boosted its stake in GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after acquiring an additional 316 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in GeneDx by 6.2% in the fourth quarter. MetLife Investment Management LLC now owns 7,750 shares of the company's stock valued at $596,000 after acquiring an additional 453 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

Analysts Set New Price Targets

WGS has been the subject of a number of research analyst reports. Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research note on Friday, May 9th. Piper Sandler assumed coverage on GeneDx in a research report on Wednesday, July 9th. They issued an "overweight" rating and a $110.00 price target for the company. TD Securities cut their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Finally, Wells Fargo & Company increased their price target on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, GeneDx has a consensus rating of "Moderate Buy" and a consensus target price of $100.38.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.